{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:31:03Z","timestamp":1792416663749,"version":"4.4.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"],"award-info":[{"award-number":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"],"award-info":[{"award-number":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"],"award-info":[{"award-number":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"],"award-info":[{"award-number":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"],"award-info":[{"award-number":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"],"award-info":[{"award-number":["UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center)"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HPTN 084 compared the safety and efficacy of long-acting injectable cabotegravir (CAB) to daily oral TDF\/FTC for prevention of HIV-1 in uninfected African women. Like a similar trial in MSM\/TGW (HPTN 083), the trial was stopped early for efficacy, expediting the need to consider introduction strategies for different populations. We examine survey and qualitative data from a four-country sub-study to examine oral and injectable PrEP acceptability and considerations for CAB access among African women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants completed baseline and follow-up surveys on HIV risk perception, sexual behavior. product acceptability and adherence during the blinded trial. Additionally, up to two in-depth interviews each with 73 sub-study participants explored product use and trial-related experiences, during the blinded and unblinded study periods. Using survey data, we classified participants as: engaged in female sex work (FSW), having multiple non-transactional partners, or monogamous. A study statistician identified participants\u2019 assigned study arm. We followed a thematic analysis process to read transcripts, develop a codebook and apply codes in NVivo to transcripts with intermittent intercoder reliability checks; using Excel matrices to explore differences across risk categories and study arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Participants overwhelmingly preferred injections to pills, appreciating the ease, convenience, and privacy of a long-acting formulation. Many participants described challenges with contraceptive and\/or study pill adherence, impeded by late night work, unexpected travel, or heavy drinking. Women in the TDF\/FTC arm were more likely to describe side effects, compared to those in the CAB arm. Pain also varied widely by study arm. When considering post-trial access to CAB, limited PrEP knowledge, cost and concerns around stigma and poor service quality were potential access barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women\u2019s desire for privacy and ease of use outweighed injectable concerns, resulting in a strong preference for CAB. Cost and accessibility will need to be addressed by implementation programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0309811","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:27:17Z","timestamp":1729690037000},"page":"e0309811","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-3675","authenticated-orcid":true,"given":"Elizabeth E.","family":"Tolley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Bula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miria","family":"Chitukuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomhle","family":"Ndimande-Khoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Etima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Namey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Kemigisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lerato","family":"Makhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Tsidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-7613","authenticated-orcid":true,"given":"Marie","family":"Shoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2174-313X","authenticated-orcid":true,"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Delany- Moretlwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the HPTN 084 study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"pone.0309811.ref001","unstructured":"UNAIDS. Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. 2021."},{"key":"pone.0309811.ref002","unstructured":"CDC Statement on FDA Approval of Drug for HIV Prevention [Internet]. Atlanta, GA; 2012 [cited April 13, 2022]. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2012\/FDA-ApprovesDrugStatement.html"},{"key":"pone.0309811.ref003","unstructured":"World Health Organization. Guildeline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva, Switzerland: 2015."},{"key":"pone.0309811.ref004","unstructured":"Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Switzerland: WHO, 2016."},{"key":"pone.0309811.ref005","unstructured":"FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epiidemic [Internet]. 2019 [cited April 13, 2022]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic"},{"issue":"Suppl 4","key":"pone.0309811.ref006","doi-asserted-by":"crossref","first-page":"e25298","DOI":"10.1002\/jia2.25298","article-title":"HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery","volume":"22","author":"CL Celum","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pone.0309811.ref007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12879-018-3463-4","article-title":"A systematic review of adherence to oral pre-exposure prophylaxis for HIV\u2014how can we improve uptake and adherence?","volume":"18","author":"D Sidebottom","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"5","key":"pone.0309811.ref008","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QAI.0000000000000362","article-title":"Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP","volume":"67","author":"A Corneli","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"pone.0309811.ref009","doi-asserted-by":"crossref","first-page":"e106410","DOI":"10.1371\/journal.pone.0106410","article-title":"The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa","volume":"9","author":"J Headley","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pone.0309811.ref010","doi-asserted-by":"crossref","first-page":"e89118","DOI":"10.1371\/journal.pone.0089118","article-title":"Women\u2019s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa","volume":"9","author":"A van der Straten","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"pone.0309811.ref011","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0309811.ref012","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0309811.ref013","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1473-3099(18)30428-6","article-title":"Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"S Delany-Moretlwe","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0309811.ref014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0309811.ref015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0b013e31824a060b","article-title":"What\u2019s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples","volume":"59","author":"NC Ware","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0309811.ref016","unstructured":"Baeten JMPP, T.; Mgodi, N.; Ramjee, G.; Gati, B.; Mhlanga, F.;, Hunidzarira, P.; et al, editor High adherence and sustained impact on HIV\u20101 incidence: Final results of an open\u2010label extension trial of the dapivirine vaginal ring. 10th IAS Conference on HIV Science; 2019; Mexico City, Mexico: International AIDS Society"},{"issue":"11","key":"pone.0309811.ref017","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2024.0464","article-title":"HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women","volume":"331","author":"J Marrazzo","year":"2024","journal-title":"JAMA"},{"key":"pone.0309811.ref018","doi-asserted-by":"crossref","first-page":"e26069","DOI":"10.1002\/jia2.26069","article-title":"Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya","volume":"26","author":"M Ogollo","year":"2023","journal-title":"Journal of the International AIDS Society"},{"issue":"9","key":"pone.0309811.ref019","doi-asserted-by":"crossref","first-page":"e1002885","DOI":"10.1371\/journal.pmed.1002885","article-title":"Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya","volume":"16","author":"KK Mugwanya","year":"2019","journal-title":"PLoS Med"},{"issue":"6","key":"pone.0309811.ref020","doi-asserted-by":"crossref","first-page":"e1003670","DOI":"10.1371\/journal.pmed.1003670","article-title":"PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial","volume":"18","author":"C Celum","year":"2021","journal-title":"PLoS Med"},{"issue":"10","key":"pone.0309811.ref021","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/S2352-3018(22)00195-3","article-title":"Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial","volume":"9","author":"J Velloza","year":"2022","journal-title":"Lancet HIV"},{"issue":"10337","key":"pone.0309811.ref022","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"S Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"pone.0309811.ref023","unstructured":"Delaney-Moretlwe S, Hanscom B, F. A, Dadabhai S, Gadama D, Mirembe B, et al. Initial PrEP product choice: results from the HPTN 084 open-label extension. the 12th IAS Conference on HIV Science; 26 July, 2023; Brisbane, Australia: International AIDS Society 2023."},{"issue":"1","key":"pone.0309811.ref024","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/QAI.0000000000001556","article-title":"Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring","volume":"77","author":"JE Balkus","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0309811.ref025","volume-title":"Qualitative Methods in Public Health","author":"EE Tolley","year":"2016","edition":"2"},{"issue":"e25408","key":"pone.0309811.ref026","article-title":"Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)","volume":"22","author":"EE Tolley","year":"2019","journal-title":"Journal of the International AIDS Society"},{"issue":"9","key":"pone.0309811.ref027","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","article-title":"Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077","volume":"24","author":"EE Tolley","year":"2020","journal-title":"AIDS Behav"},{"issue":"epub25094","key":"pone.0309811.ref028","first-page":"1","article-title":"The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention","volume":"21","author":"A Van der Straten","year":"2018","journal-title":"Journal of International AIDS Society"},{"issue":"5","key":"pone.0309811.ref029","doi-asserted-by":"crossref","first-page":"e26088","DOI":"10.1002\/jia2.26088","article-title":"Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya","volume":"26","author":"NJ Wara","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"pone.0309811.ref030","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1007\/s10461-017-2017-x","article-title":"Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States","volume":"22","author":"D Kerrigan","year":"2018","journal-title":"AIDS Behav"},{"issue":"10","key":"pone.0309811.ref031","doi-asserted-by":"crossref","first-page":"e0258542","DOI":"10.1371\/journal.pone.0258542","article-title":"Adolescent girls and young women\u2019s PrEP-user journey during an implementation science study in South Africa and Kenya","volume":"16","author":"E Rousseau","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"pone.0309811.ref032","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/QAI.0000000000001093","article-title":"Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study","volume":"73","author":"ST Roberts","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"pone.0309811.ref033","doi-asserted-by":"crossref","first-page":"e0228620","DOI":"10.1371\/journal.pone.0228620","article-title":"Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa","volume":"15","author":"D Pillay","year":"2020","journal-title":"PLoS One"},{"key":"pone.0309811.ref034","article-title":"Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program","author":"J Pintye","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0309811.ref035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.socscimed.2014.03.021","article-title":"Hidden harms: women\u2019s narratives of intimate partner violence in a microbicide trial, South Africa","volume":"110","author":"J Stadler","year":"2014","journal-title":"Soc Sci Med"},{"issue":"1","key":"pone.0309811.ref036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12977-018-0408-3","article-title":"Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?","volume":"15","author":"R Eakle","year":"2018","journal-title":"Retrovirology"},{"issue":"Suppl 2","key":"pone.0309811.ref037","doi-asserted-by":"crossref","first-page":"e26107","DOI":"10.1002\/jia2.26107","article-title":"Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition","volume":"26","author":"L Lorenzetti","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"pone.0309811.ref038","article-title":"Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women","author":"CJJ van Vuuren","year":"2023","journal-title":"AIDS and Behavior"},{"issue":"2","key":"pone.0309811.ref039","doi-asserted-by":"crossref","first-page":"e0191251","DOI":"10.1371\/journal.pone.0191251","article-title":"Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study","volume":"13","author":"M Atujuna","year":"2018","journal-title":"PLoS One"},{"key":"pone.0309811.ref040","unstructured":"Department of Health. Updated Guidelines for the Provision of Oral Pre-exposure Prophylaxix (PrEP) to Persons at Sustantial Risk of HIV Infection. Pretoria: National Department of Health, 2021."},{"key":"pone.0309811.ref041","doi-asserted-by":"crossref","first-page":"e26106","DOI":"10.1002\/jia2.26106","article-title":"What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations","volume":"26","author":"G Meyer-Rath","year":"2023","journal-title":"Journal of the International AIDS Society"},{"key":"pone.0309811.ref042","doi-asserted-by":"crossref","first-page":"e26101","DOI":"10.1002\/jia2.26101","article-title":"Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries","volume":"26","author":"SY Jenkins","year":"2023","journal-title":"Journal of the International AIDS Society"},{"key":"pone.0309811.ref043","doi-asserted-by":"crossref","first-page":"e26110","DOI":"10.1002\/jia2.26110","article-title":"Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review","volume":"26","author":"D Castor","year":"2023","journal-title":"Journal of the International AIDS Society"},{"key":"pone.0309811.ref044","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fpubh.2018.00188","article-title":"Pre-exposure Prophylaxis: The Delivery Challenge","volume":"6","author":"WDF Venter","year":"2018","journal-title":"Front Public Health"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:27:33Z","timestamp":1729690053000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309811"}},"subtitle":[],"editor":[{"given":"Tinashe","family":"Mudzviti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309811","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}